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South African ischaemic stroke 
guideline, 2010
To the Editor: We believe the guideline by Bryer et al.¹ to be 
overdue and well constructed, and generally to contain excellent 
recommendations. However, the authors note that intravenous tissue 
plasminogen activator (tPA) ‘is an accepted therapy’ and ‘significantly 
improves outcome’; particular reference is made to the ECASS III 
trial2 to justify its use within 4.5 hours of stroke onset. We believe that 
this is a dangerous and unsupported recommendation.
Most of the initial thrombolysis trials in stroke were negative; 
some were stopped early due to harm. The ethics that would allow 
more trials to continue in the light of such existing studies are hard 
to conceive, but permission was granted and the NINDS trial finally 
reported a positive outcome.3 However, NINDS was a relatively small 
study (312 patients received thrombolytic therapy with tPA), and 
significantly higher scores for stroke severity in the placebo group 
could explain the improved outcome attributed to thrombolysis. 
Others have re-analysed the NINDS data and shown no improvement 
in outcome.4 This takes no consideration of the massively increased 
intra-cerebral bleed rate in the treatment arm (6.4% v. 0.6%). 
Furthermore, conflicts of interest were not well disclosed; for 
instance Genentech, the manufacturer of tPA, contributed US$11 
million to the American Heart Association, and paid for its national 
headquarters in Dallas.5
There are many flaws in the ECASS III trial.² Patients in the 
treatment group were younger, and had lower stroke severity scores 
and fewer prior strokes. Although the Modified Rankin Scale was 
7% better in the treated group, the rate of symptomatic intracranial 
haemorrhage was 2.5% v. 0.2%; the 90-day mortality was the same in 
both groups. Like NINDS, ECASS III was massively funded by the 
pharmaceutical industry. Previous studies with similar design, such 
as the ATLANTIS trial, were stopped early due to harm.6
There have been over 940 trials of pharmacological treatment for 
acute ischaemic stroke; 20% (with over 16 000 patients), of which 
the majority were funded by pharmaceutical companies,7 have never 
been reported in full. 
The emphasis of the guideline1 on treating stroke as an emergency, 
establishing stroke centres, and providing high-quality supportive 
treatment (to prevent secondary brain injury) is highly commended. 
There is no compelling evidence to support the use of tPA in stroke; 
its use beyond 3 hours is dangerous, and it should not form part of 
national guidelines.  
The authors have no conflicts of interest to declare.
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Dr Alan Bryer replies: I thank Wallis and Lahri for their comments 
on the stroke guideline. A new treatment always requires a 
balance between potential benefits and harm. However, it was 
felt that the potential benefits of treatment have been shown to 
reasonably outweigh the potential harm. Wallis and Lahri alluded 
to possible collusion between Genentech, which manufactures tissue 
plasminogen activator (tPA) in the USA, and the American Heart/
Stroke Association concerning their recommendation for use of 
IVI tPA in their stroke guideline and by implication the Food and 
Drug Administration (FDA) approval of the use of tPA for acute 
ischaemic stroke. This seems unlikely and would not apply to the 
other countries and their respective professional bodies or stroke 
organisations and independent regulatory authorities. Nevertheless 
I acknowledge and share their concerns about drug company 
sponsorship in the stroke trials, which is also commonplace in other 
large clinical trials. Although the ideal would be for all studies to be 
investigator led without pharmaceutical company involvement, the 
large trials needed to confirm or refute drug efficacy are difficult to 
perform without their backing. 
Initial thrombolysis studies using streptokinase were stopped 
because it appeared to cause harm in the doses used. However, 
evidence for the benefit of tPa within 3 hours of onset of ischaemic 
stroke is robust. A Cochrane review on thrombolysis for acute 
ischaemic stroke included 26 trials with data on 7 152 patients 
testing urokinase, streptokinase, tPA, recombinant prourokinase 
or desmoteplase with 56% of all data that came from trials testing 
tPA – 11 trials, 3 977 patients.1 Overall, tPA significantly reduced the 
proportion of patients with poor outcomes after stroke and increased 
the proportion with good outcomes. This benefit at 3 months 
was apparent despite a non-significant increase in deaths, mostly 
attributable to intracranial haemorrhage. The authors concluded that 
the available evidence supported the clinical use of tPA within the 
existing licence. However, current data are insufficient to determine 
risks and benefits in certain subgroups of patients, especially those 
aged 80 years and older.
The European Medicines Evaluation Agency granted licence in 
2002 for the use of tPA for treating ischaemic stroke patients within 3 
hours of symptom onset on condition of completing: (i) a prospective 
registry of patient treatment experience with tPA given within 
the 3-hour window from symptom onset (Safe Implementation of 
Thrombolysis in Stroke Monitoring Study (SITS-MOST));2 and 
(ii) a prospective, randomised, placebo-controlled trial of tPA 
administered between 3 and 4.5 hours after stroke onset, ECASS-
III. Under European Union regulations, SITS-MOST was required 
to assess the safety profile of tPA in clinical practice by comparison 
with results in randomised controlled trials. A total of 6 483 patients 
were recruited from 285 centres (50% with little previous experience 
in stroke thrombolysis) in 14 countries for this prospective, open, 
monitored, observational study. Primary outcomes were symptomatic 
(a deterioration in National Institutes of Health stroke scale score of 
≥4) intracerebral haemorrhage within 24 hours, and mortality at 
3 months. Mortality, the proportion of patients with symptomatic 
intracerebral haemorrhage as per the Cochrane definition, and 
functional outcome at 3 months were compared with pooled results 
from randomised controlled trials. Results from the SITS-MOST 
study found that intravenous tPA is safe and effective in routine 
clinical use within 3 hours of stroke onset, even by centres with little 
previous experience of thrombolytic therapy for acute stroke. They 
encouraged wider use of thrombolytic therapy for suitable patients 
treated in stroke centres.
The UK National Institute for Health Care and Clinical Excellence 
reviewed the Cochrane review and the results of the meta-analysis 
(including the undue weight of the NINDS trial in the meta-analysis) 
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and the results of large observational studies such as SITS-MOST and 
concluded that tPA was effective in the treatment of acute ischaemic 
stroke.3 Another pooled analysis of individual data of six tPA trials 
showed that, even within a 3-hour window, earlier treatment results 
in a better outcome (0 - 90 minutes: odds ratio (OR) 2.11, 95% 
confidence interval (CI) 1.33 - 3.55; 90 - 180 minutes: OR 1.69; 
95% CI 1.09 - 2.62) and suggested a benefit up to 4.5 hours.4 The 
ECASS III trial found tPA to be effective when provided up to 4.5 
hours after stroke onset (OR 1.34, 95% CI 1.02 - 1.76, p=0.04). There 
was a significant increase in symptomatic intracranial haemorrhage 
(2.7% v. 0.3%), but no significant effect on mortality. In another 
study the SITS investigators compared 664 patients with ischaemic 
stroke treated between 3 and 4.5 hours with 11 865 patients treated 
within 3 hours.5 There were no significant differences between the 
3 - 4.5-hour cohort and the 3-hour cohort for any outcome measures, 
confirming that tPA remains safe when given between 3 and 4.5 
hours after the onset of symptoms in ischaemic stroke patients who 
otherwise fulfil the European summary of product characteristics 
criteria. A systematic review of four trials, including ECAS III, 
confirmed that tPA given between 3 and 4.5 hours after stroke onset 
is associated with an increased chance of favourable outcome (OR 
1.31, 95% CI 1.10 - 1.56, p=0.002) with no significant difference in 
mortality compared with placebo, thus strengthening the evidence 
that treatment with tPA in the 3 - 4.5-hour window is beneficial and 
should therefore be considered for stroke patients who present during 
this time window.6
The recommendation for the use of IVI tPA within 4.5 hours 
of onset of ischaemic stroke in the new South African guideline 
is the same as in the guidelines of other countries including the 
USA, Canada, the European Union, Scandinavia and Australia. The 
evidence shows that IVI tPA treatment benefits selected patients but 
should be delivered in well-equipped and skilled emergency units 
and/or stroke units with adequate expertise and infrastructure for 
monitoring, rapid assessment and investigation of acute patients. Such 
patients should be offered treatment with tPA provided the potential 
risks and benefits are explained to them and their attendant families. 
Collaboration is recommended between clinicians in pre-hospital 
services, emergency medicine, neurology and neuroradiology for 
prompt identification of potentially eligible patients, patient selection, 
audit and quality improvement initiatives.
Will National Health Insurance ensure 
the national health?
To the Editor: The good intentions in the proposed National Health 
Insurance (NHI) scheme are not doubted, but I suspect that the 
authorities have not been correctly advised on why the health system 
is often inadequate.
South Africa’s health system provides private health care access 
to some, but the large majority depends on the state for health 
services. Private health care appears to offer a better service than state 
health care because of a lack of adequate state sector infrastructure. 
However, injecting massive NHI funding into state health will result 
in a burgeoning bureaucracy and little to improve our citizens’ health 
experience.
Infrastructure, from equipment to health care personnel, is limited 
in the state health system and patients experience many irritations 
and inconveniences because of the way it operates.
There is no reason why repeat outpatients cannot have appointments 
instead of all having to attend the health facility before dawn only to 
be seen hours later. With appointments the number of patients in 
a health facility would become more manageable and patients who 
work would not lose pay by waiting unnecessarily.
Why do patients have to return, often after long journeys, to 
collect repeat medication instead of accessing it at their nearest 
state health facility? Private sector prescriptions are on a computer 
and available at supermarket pharmacies nationwide. State health 
facilities can use such computer programmes and reduce outpatient 
and clinic numbers by 30%. And why do supermarkets have better 
baby-changing facilities than our health facilities, which often do not 
have any at all?
Patient self-triage is another serious patient-perceived problem. 
For budgetary and administrative reasons state health services are 
classified as primary or district, secondary or regional, and tertiary 
or academic. The family with a sick baby is expected to self-triage the 
baby into one of these categories. Heaven help them if they appear 
at a secondary or tertiary hospital with a primary care condition, 
as they may be denied treatment and referred back. Since when do 
health facilities turn away patients? Health facilities must recognise 
that their concept of an emergency differs from that of a lay person 
and act accordingly!
The state health services have some excellent health practitioners, 
but there are not enough of them. Most are concentrated in urban areas 
and medical schools, and although this is unlikely to change, the rural 
paucity of practitioners could be addressed in part by the following.
Firstly, address the overall numbers of health practitioners in the 
state services. One cannot buy, but must attract and retain the best 
personnel. This is not just about money, and the nine provincial 
health departments and the eight university medical schools must 
play a role in this joint approach and responsibility. Provinces with 
medical schools must accept the obligation of providing state-of-the-
art equipment and consumables to the teaching environment. It is 
unacceptable that cardiac procedures be delayed because the budget 
for stents is insufficient, or that patients should suffer long delays 
because the prosthetic hips budget is exhausted. 
Secondly, as part of their co-responsibility for patients the medical 
schools must recognise that the health department’s responsibility for 
the patients in a teaching hospital extends throughout the province. 
In recognising this health and teaching continuum the medical 
schools should co-operate in outreach programmes throughout and 
across provinces to take treatment to where the patients live, subject 
to the provinces meeting their equipment obligations. They must 
also recognise the medical practitioner needs in South Africa and 
support the front-line health care disciplines of family medicine and 
emergency medicine.
The present state health system could be remedied by wise 
investment in real patient care at less than an NHI would cost, and 
without creating another bureaucracy.
Alan Mac Mahon
alanjean@telkomsa.net
CORRESPONDENCE
1.    Wardlaw JM, Murray V, Berge E, del Zoppo G. Thrombolysis for acute ischaemic stroke. Stroke 
2010;41:e445-e446. 
2.    Wahlgren N, Ahmed N, Da´valos A, et al.; SITS-MOST Investigators. Thrombolysis with alteplase for 
acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-
MOST): an observational study. Lancet 2007;369:275-282. [published correction appears in Lancet 
2007;369:826]
3.    National Institute for Health and Clinical Excellence. Altepase for the treatment of acute ischaemic 
stroke (TA 122). London: NICE, 2007; updated 2010.
4.    Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis 
of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774. 
5.    Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke 
(SITS-ISTR): an observational study. Lancet 2008;372:1303-1309.
6.    Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours 
after acute ischemic stroke. A meta-analysis. Stroke 2009;40:2438-2441.
